<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371522</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-4303</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Immunotherapy advances</Title><ISOAbbreviation>Immunother Adv</ISOAbbreviation></Journal><ArticleTitle>A rapid method to assess the <i>in vivo</i> multi-functionality of adoptively transferred engineered TCR T cells.</ArticleTitle><Pagination><StartPage>ltae007</StartPage><MedlinePgn>ltae007</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ltae007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/immadv/ltae007</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The clinical efficacy of chimeric antigen and T cell receptor (TCR) T cell immunotherapies is attributed to their ability to proliferate and persist <i>in vivo</i>. Since the interaction of the engineered T cells with the targeted tumour or its environment might suppress their function, their functionality should be characterized not only before but also after adoptive transfer.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">We sought to achieve this by adapting a recently developed Severe acute respiratory syndrome <i>coronavirus 2</i> (SARS-CoV-2) rapid whole blood T cell assay to stimulate engineered TCR T cells in small volumes of whole blood (&lt;1 ml) without <i>in vitro</i> cellular purification. As a proof-of-concept, we used this method to longitudinally study two patients with primary Hepatitis B Virus (HBV)-related hepatocellular carcinoma who received multiple dose-escalating infusions of transiently functional mRNA-engineered HBV-TCR T cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We demonstrated that a simple pulsing of whole blood with a peptide corresponding to the epitope recognized by the specific HBV-TCR elicited Th1 cytokine secretion in both patients only after HBV-TCR T cell treatment and not before. The amount of cytokines secreted also showed an infusion-dose-dependent association.</AbstractText><AbstractText Label="DISCUSSIONS" NlmCategory="UNASSIGNED">These findings support the utility of the whole blood cytokine release assay in monitoring the <i>in vivo</i> function and quantity of engineered T cell products following adoptive transfer.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Anthony T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0003-0079-8203</Identifier><AffiliationInfo><Affiliation>Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hang</LastName><ForeName>Shou Kit</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0002-4169-7209</Identifier><AffiliationInfo><Affiliation>Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamoorthy</LastName><ForeName>Thinesh L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Wan Cheng</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Regina Wanju</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Lion TCR Pte Ltd., Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wai</LastName><ForeName>Lu-En</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Lion TCR Pte Ltd., Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoletti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2942-0485</Identifier><AffiliationInfo><Affiliation>Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunother Adv</MedlineTA><NlmUniqueID>101776979</NlmUniqueID><ISSNLinking>2732-4303</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T cell therapy</Keyword><Keyword MajorTopicYN="N">adoptive cell transfer</Keyword><Keyword MajorTopicYN="N">hepatitis B</Keyword><Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword></KeywordList><CoiStatement>The authors disclose the following: A.B. and A.T.T. are the Scientific Founder and the Scientific Consultant of Lion TCR Pte. Ltd. respectively, a biotech company developing T cell receptors for treatment of virus-related diseases and cancers. R.W.W and L-E.W. are employees of Lion TCR Pte. Ltd. All other authors disclose no conflicts. Lion TCR Pte. Ltd. has a patent application related to this work (WO2021148110A1).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371522</ArticleId><ArticleId IdType="pmc">PMC11452736</ArticleId><ArticleId IdType="doi">10.1093/immadv/ltae007</ArticleId><ArticleId IdType="pii">ltae007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blumenberg V, Busch G, Baumann S. et al.. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL. Blood Adv 2023; 7:6844–9. 10.1182/bloodadvances.2023010364</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2023010364</ArticleId><ArticleId IdType="pmc">PMC10679803</ArticleId><ArticleId IdType="pubmed">37748131</ArticleId></ArticleIdList></Reference><Reference><Citation>Turicek DP, Giordani VM, Moraly J. et al.. CAR T-cell detection scoping review: an essential biomarker in critical need of standardization. J ImmunoTher Cancer 2023; 11(5):e006596. 10.1136/jitc-2022-006596</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2022-006596</ArticleId><ArticleId IdType="pmc">PMC10230989</ArticleId><ArticleId IdType="pubmed">37217245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumber D, Wang LD.. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine 2022; 77:103941. 10.1016/j.ebiom.2022.103941</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103941</ArticleId><ArticleId IdType="pmc">PMC8927848</ArticleId><ArticleId IdType="pubmed">35301179</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty GL, O’Hara MH, Lacey SF. et al.. Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a Phase 1 trial. Gastroenterology 2018; 155:29–32. 10.1053/j.gastro.2018.03.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.03.029</ArticleId><ArticleId IdType="pmc">PMC6035088</ArticleId><ArticleId IdType="pubmed">29567081</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JB, Barrett DM, Kariko K.. The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy. Mol Ther 2019; 27(4):747–56. 10.1016/j.ymthe.2019.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.01.018</ArticleId><ArticleId IdType="pmc">PMC6453504</ArticleId><ArticleId IdType="pubmed">30819612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenderian SS, Ruella M, Shestova O. et al.. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015; 29:1637–47. 10.1038/leu.2015.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.52</ArticleId><ArticleId IdType="pmc">PMC4644600</ArticleId><ArticleId IdType="pubmed">25721896</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug C, Wiesinger M, Abken H. et al.. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother 2014; 63:999–1008. 10.1007/s00262-014-1572-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-014-1572-5</ArticleId><ArticleId IdType="pmc">PMC11029092</ArticleId><ArticleId IdType="pubmed">24938475</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F, Zhao J, Tan AT. et al.. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatol Int 2021; 15:1402–12. 10.1007/s12072-021-10250-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-021-10250-2</ArticleId><ArticleId IdType="pmc">PMC8651587</ArticleId><ArticleId IdType="pubmed">34850325</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Yang N, Lee Krishnamoorthy T. et al.. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019; 156:1862–76.e9. 10.1053/j.gastro.2019.01.251</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.01.251</ArticleId><ArticleId IdType="pubmed">30711630</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Bertoletti A.. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunother Adv 2022; 2:ltab026. 10.1093/immadv/ltab026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/immadv/ltab026</ArticleId><ArticleId IdType="pmc">PMC9327102</ArticleId><ArticleId IdType="pubmed">35919490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M, Bhakdi SC, Tan D. et al.. Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. Immunother Adv 2023; 3:ltad015. 10.1093/immadv/ltad015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/immadv/ltad015</ArticleId><ArticleId IdType="pmc">PMC10460197</ArticleId><ArticleId IdType="pubmed">37636242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Lim JM, Le Bert N. et al.. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J Clin Invest 2021; 131:e152379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409582</ArticleId><ArticleId IdType="pubmed">34623327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Meng F, Jin J. et al.. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC. Hepatol Commun 2022; 6:841–54. 10.1002/hep4.1857</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1857</ArticleId><ArticleId IdType="pmc">PMC8948543</ArticleId><ArticleId IdType="pubmed">34935312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanski HE, Eaton A, Baggott C. et al.. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv 2023; 7:541–8. 10.1182/bloodadvances.2022007246</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022007246</ArticleId><ArticleId IdType="pmc">PMC9979765</ArticleId><ArticleId IdType="pubmed">35938863</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>